Abstract:Background: Awareness of the benefits of neoadjuvant therapy is increasing, but its use as an initial therapeutic option for patients with resectable pancreatic cancer remains controversial, especially for those patients without high-risk prognostic features. Even for patients with high-risk features who are candidates to receive neoadjuvant therapy, no standard regimen exists. Methods: In this review, we examined available data on the neoadjuvant therapy in patients with resectable pancreatic cancer, including prospective studies, retrospective studies, and ongoing clinical trials, by searching PubMed/MEDLINE, ClinicalTrials.gov, Web of Science, and Cochrane Library. The characteristics and results of screened studies were described. Results: Retrospective and prospective studies with reported results and ongoing randomized studies were included. For patients with resectable pancreatic cancer, neoadjuvant therapy provides benefits such as increased survival, decreased risk of comorbidities and mortality, and improved cost-effectiveness due to an increased completion rate of multimodal treatment. Highly active regimens such as FOLFIRINOX (folinic acid, fluorouracil, irinotecan, and oxaliplatin) or gemcitabine plus nab-paclitaxel are considered acceptable therapeutic regimens. Additionally, platinum-containing regimens other than FOLFIRINOX are acceptable for selected patients. Other therapies, such as chemoradiation treatment, immtmo-oncology agents, and targeted therapies are being explored and the results are highly anticipated. Conclusion: This review highlights the benefits of neoadjuvant therapy for resectable pancreatic cancer. Some regimens are currently acceptable, but need more evidence from well-designed clinical trials or should be used after being carefully examined by a multidisciplinary team.

Penimethavone A, a flavone from a gorgonian-derived fungus Penicillium chrysogenum

Adjuvant Chemotherapy, with or Without Postoperative Radiotherapy, for Resectable Advanced Pancreatic Adenocarcinoma: Continue or Stop?

Surgical Considerations for Neoadjuvant Therapy for Pancreatic Adenocarcinoma

Neoadjuvant Treatment Strategies in Resectable Pancreatic Cancer

Neoadjuvant Therapy is Essential for Resectable Pancreatic Cancer

[Neoadjuvant Therapy for Resectable or Borderline Resectable Pancreatic Cancer]

The role of neoadjuvant therapy for resectable pancreatic cancer remains uncertain

Lamivudine plasma levels in chronic hepatitis B patients.

Neoadjuvant Therapy for Resectable Pancreatic Cancer: a Narrative Review

Current Status and Perspectives of Neoadjuvant Therapy for Pancreatic Cancer

Are We Sure that Adjuvant Chemotherapy is the Best Approach for Resectable Pancreatic Cancer? Are We in the Era of Neoadjuvant Treatment? A Review of Current Literature

Current status and prospects of neoadjuvant therapy for resectable pancreatic cancer

Preoperative therapy for pancreatic adenocarcinoma—precision beyond anatomy

The Evolving Role of Neoadjuvant Radiation Therapy in Pancreatic Adenocarcinoma

Emphasis on Neoadjuvant Therapy for “resectable”pancreatic Cancer

Narcissus and the echocardiographist.

Novel Considerations in Surgical Management of Individuals with Pancreatic Adenocarcinoma

Neoadjuvant management of locally advanced pancreatic ductal adenocarcinoma − Heading towards a promising change in treatment paradigm

Evaluation of neoadjuvant therapy for pancreatic cancer: is it the best choice?

[Developments and controversies in neoadjuvant therapy for resectable pancreatic cancer].

Analysis of the Curative Effect of Neoadjuvant Therapy on Pancreatic Cancer